

Ruben Burgos-Vargas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7688089/publications.pdf>

Version: 2024-02-01

158
papers

15,088
citations

36303

51
h-index

17592

121
g-index

168
all docs

168
docs citations

168
times ranked

11799
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2000, 343, 1520-1528.	27.0	3,651
2	Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis. <i>New England Journal of Medicine</i> , 2012, 367, 2385-2395.	27.0	716
3	Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. <i>Nature Genetics</i> , 2013, 45, 730-738.	21.4	699
4	The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. <i>Arthritis and Rheumatism</i> , 2009, 60, 1895-1905.	6.7	501
5	Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. <i>Lancet, The</i> , 2008, 372, 383-391.	13.7	486
6	Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 6-16.	0.9	397
7	Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1958-1963.	0.9	383
8	Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural damage. <i>Arthritis and Rheumatism</i> , 2011, 63, 609-621.	6.7	369
9	2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 905-908.	0.9	365
10	Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. <i>Gastroenterology</i> , 2003, 124, 288-292.	1.3	336
11	Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus. <i>Journal of Rheumatology</i> , 2019, 46, 190-197.	2.0	318
12	Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2008, 58, 3309-3318.	6.7	313
13	A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. <i>Arthritis and Rheumatism</i> , 2004, 50, 2191-2201.	6.7	307
14	Efficacy and Safety of Abatacept in Lupus Nephritis: A Twelve-Month, Randomized, Double-Blind Study. <i>Arthritis and Rheumatology</i> , 2014, 66, 379-389.	5.6	289
15	Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 328-335.	0.9	222
16	Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1. <i>Nature Communications</i> , 2015, 6, 7146.	12.8	220
17	Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2009, 60, 335-344.	6.7	216
18	ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 249-251.	0.9	208

#	ARTICLE	IF	CITATIONS
19	Long-term outcome and prognostic factors of juvenile dermatomyositis: A multinational, multicenter study of 490 patients. <i>Arthritis Care and Research</i> , 2010, 62, 63-72.	3.4	207
20	Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2010, 62, 1792-1802.	6.7	204
21	Epidemiology of the Rheumatic Diseases in Mexico. A Study of 5 Regions Based on the COPCORD Methodology. <i>Journal of rheumatology Supplement</i> , The, 2011, 86, 3-8.	2.2	200
22	Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1016-1023.	0.9	188
23	Treating juvenile idiopathic arthritis to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrhumdis-2018-213030.	0.9	183
24	MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1550-1558.	0.9	171
25	A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2006, 54, 2989-2996.	6.7	133
26	Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: A randomized, double-blind trial. <i>Arthritis and Rheumatism</i> , 2011, 63, 1543-1551.	6.7	125
27	Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. <i>The Lancet Child and Adolescent Health</i> , 2019, 3, 255-263.	5.6	120
28	The early clinical recognition of juvenile-onset ankylosing spondylitis and its differentiation from juvenile rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1995, 38, 835-844.	6.7	116
29	Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1114-1122.	0.9	106
30	Anti-tumor necrosis factor $\hat{\pm}$ blockade in the treatment of juvenile spondylarthropathy. <i>Arthritis and Rheumatism</i> , 2005, 52, 2103-2108.	6.7	104
31	Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1991-1997.	0.9	103
32	Treatment Algorithms in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2015, 67, 1237-1245.	3.4	88
33	Tocilizumab Inhibits Structural Joint Damage and Improves Physical Function in Patients with Rheumatoid Arthritis and Inadequate Responses to Methotrexate: LITHE Study 2-year Results. <i>Journal of Rheumatology</i> , 2013, 40, 113-126.	2.0	87
34	<i>ERAP2</i> is associated with ankylosing spondylitis in <i>HLA-B27</i> -positive and <i>HLA-B27</i> -negative patients. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1627-1629.	0.9	86
35	Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1311-1317.	0.9	85
36	A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis-Related Arthritis. <i>Arthritis Care and Research</i> , 2015, 67, 1503-1512.	3.4	84

#	ARTICLE	IF	CITATIONS
37	Use of a numerical rating scale as an answer modality in ankylosing spondylitis-specific questionnaires. <i>Arthritis and Rheumatism</i> , 2002, 47, 242-248.	6.7	82
38	The Concept of Axial Spondyloarthritis: Joint Statement of the Spondyloarthritis Research and Treatment Network and the Assessment of SpondyloArthritis international Society in Response to the US Food and Drug Administration's Comments and Concerns. <i>Arthritis and Rheumatology</i> , 2014, 66, 2649-2656.	5.6	81
39	JUVENILE-ONSET SPONDYLOARTHROPATHIES. <i>Rheumatic Disease Clinics of North America</i> , 1997, 23, 569-598.	1.9	78
40	Differential Features Between Primary Ankylosing Spondylitis and Spondylitis Associated with Psoriasis and Inflammatory Bowel Disease. <i>Journal of Rheumatology</i> , 2011, 38, 1656-1660.	2.0	77
41	FEATURES OF SPONDYLOARTHRITIS AROUND THE WORLD. <i>Rheumatic Disease Clinics of North America</i> , 1998, 24, 753-770.	1.9	73
42	Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout. <i>Arthritis Care and Research</i> , 2019, 71, 427-434.	3.4	73
43	The Pediatric Rheumatology International Trials Organization/American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: Prospective validation of the definition of improvement. <i>Arthritis and Rheumatism</i> , 2006, 55, 355-363.	6.7	72
44	Gender differences among patients with primary ankylosing spondylitis and spondylitis associated with psoriasis and inflammatory bowel disease in an iberoamerican spondyloarthritis cohort. <i>Medicine (United States)</i> , 2016, 95, e5652.	1.0	72
45	Long-Term Safety, Efficacy, and Quality of Life in Patients With Juvenile Idiopathic Arthritis Treated With Intravenous Abatacept for Up to Seven Years. <i>Arthritis and Rheumatology</i> , 2015, 67, 2759-2770.	5.6	64
46	Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study. <i>RMD Open</i> , 2021, 7, e001450.	3.8	64
47	Validation of the Health Assessment Questionnaire disability index in patients with gout. <i>Arthritis and Rheumatism</i> , 2008, 59, 665-669.	6.7	63
48	The assessment of the spondyloarthritis international society concept and criteria for the classification of axial spondyloarthritis and peripheral spondyloarthritis: A critical appraisal for the pediatric rheumatologist. <i>Pediatric Rheumatology</i> , 2012, 10, 14.	2.1	59
49	Diagnosis of Chronic Gout: Evaluating the American College of Rheumatology Proposal, European League Against Rheumatism Recommendations, and Clinical Judgment. <i>Journal of Rheumatology</i> , 2010, 37, 1743-1748.	2.0	55
50	Metabolic Syndrome and Ischemic Heart Disease in Gout. <i>Journal of Clinical Rheumatology</i> , 2004, 10, 105-109.	0.9	54
51	<i>In Vivo</i> Peripheral Blood Proinflammatory T Cells in Patients with Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2012, 39, 830-835.	2.0	53
52	The juvenile-onset spondyloarthritis. <i>Rheumatic Disease Clinics of North America</i> , 2002, 28, 531-560.	1.9	52
53	Current therapies in rheumatoid arthritis: A Latin American perspective. <i>Reumatología Clínica</i> , 2013, 9, 106-112.	0.5	50
54	Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises. <i>Arthritis Care and Research</i> , 2016, 68, 667-672.	3.4	48

#	ARTICLE	IF	CITATIONS
55	Catastrophic health expenses and impoverishment of households of patients with rheumatoid arthritis. <i>Reumatología Clínica</i> , 2012, 8, 168-173.	0.5	47
56	Two-year Efficacy and Safety of Etanercept in Pediatric Patients with Extended Oligoarthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2016, 43, 816-824.	2.0	46
57	Comparison of the Clinical Expression of Patients with Ankylosing Spondylitis from Europe and Latin America. <i>Journal of Rheumatology</i> , 2012, 39, 2315-2320.	2.0	44
58	Efficacy and Tolerability of Celecoxib in the Treatment of Acute Gouty Arthritis: A Randomized Controlled Trial. <i>Journal of Rheumatology</i> , 2012, 39, 1859-1866.	2.0	44
59	The prevalence and clinical characteristics of nonradiographic axial spondyloarthritis among patients with inflammatory back pain in rheumatology practices: a multinational, multicenter study. <i>Arthritis Research and Therapy</i> , 2016, 18, 132.	3.5	42
60	Primary prevention in rheumatology: the importance of hyperuricemia. <i>Best Practice and Research in Clinical Rheumatology</i> , 2004, 18, 111-124.	3.3	39
61	The LMP2 polymorphism is associated with susceptibility to acute anterior uveitis in HLA-B27 positive juvenile and adult Mexican subjects with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 1997, 56, 488-492.	0.9	37
62	Characterization of B27 haplotypes by oligotyping and genomic sequencing in the Mexican Mestizo population with ankylosing spondylitis: Juvenile and adult onset. <i>Human Immunology</i> , 1995, 43, 174-180.	2.4	36
63	Tumor Necrosis Factor- α Promoter Polymorphisms in Mexican Patients With Spondyloarthritis. <i>Human Immunology</i> , 2006, 67, 826-832.	2.4	36
64	Vitiligo Improvement in a Patient with Ankylosing Spondylitis Treated with Infliximab. <i>Dermatology</i> , 2008, 216, 234-235.	2.1	36
65	Response to Expression of Concern Regarding VIGOR Study. <i>New England Journal of Medicine</i> , 2006, 354, 1196-1199.	27.0	35
66	Current smoking status is associated to a non-ACR 50 response in early rheumatoid arthritis. A cohort study. <i>Clinical Rheumatology</i> , 2011, 30, 1589-1593.	2.2	35
67	Epidemiology of Rheumatic Diseases. A Community-Based Study in Urban and Rural Populations in the State of Nuevo Leon, Mexico. <i>Journal of rheumatology Supplement, The</i> , 2011, 86, 9-14.	2.2	34
68	Validity of the COPCORD Core Questionnaire as a Classification Tool for Rheumatic Diseases. <i>Journal of rheumatology Supplement, The</i> , 2011, 86, 31-35.	2.2	34
69	The place of juvenile onset spondyloarthropathies in the Durban 1997 ILAR classification criteria of juvenile idiopathic arthritis. <i>International League of Associations for Rheumatology. Journal of Rheumatology</i> , 2002, 29, 869-74.	2.0	34
70	Prevalence of Comorbidities and Risk Factors for Comorbidities in Patients with Spondyloarthritis in Latin America: A Comparative Study with the General Population and Data from the ASAS-COMOSPA Study. <i>Journal of Rheumatology</i> , 2018, 45, 206-212.	2.0	31
71	Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1). <i>Rheumatology</i> , 2020, 59, 2774-2784.	1.9	31
72	Spondyloarthropathies and psoriatic arthritis in children. <i>Current Opinion in Rheumatology</i> , 1993, 5, 634-643.	4.3	29

#	ARTICLE	IF	CITATIONS
73	Association study of LMP gene polymorphisms in Mexican patients with spondyloarthritis. <i>Human Immunology</i> , 2004, 65, 1437-1442.	2.4	29
74	Prevalence of Rheumatic Regional Pain Syndromes in Adults from Mexico: A Community Survey Using COPCORD for Screening and Syndrome-specific Diagnostic Criteria. <i>Journal of rheumatology Supplement, The</i> , 2011, 86, 15-20.	2.2	29
75	Development and initial validation of composite parent- and child-centered disease assessment indices for juvenile idiopathic arthritis. <i>Arthritis Care and Research</i> , 2011, 63, 1262-1270.	3.4	27
76	Catastrophic health expenses and impoverishment of households of patients with rheumatoid arthritis. <i>Reumatología Clínica (English Edition)</i> , 2012, 8, 168-173.	0.3	27
77	Function of Treg Cells Decreased in Patients With Systemic Lupus Erythematosus Due To the Effect of Prolactin. <i>Medicine (United States)</i> , 2016, 95, e2384.	1.0	27
78	Coping Strategies for Health and Daily-Life Stressors in Patients With Rheumatoid Arthritis, Ankylosing Spondylitis, and Gout. <i>Medicine (United States)</i> , 2015, 94, e600.	1.0	23
79	JUVENILE ANKYLOSING SPONDYLITIS. <i>Rheumatic Disease Clinics of North America</i> , 1992, 18, 123-142.	1.9	23
80	Pharmacokinetics of Meloxicam in Patients With Juvenile Rheumatoid Arthritis. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 866-872.	2.0	22
81	The diagnostic value of the proposal for clinical gout diagnosis (CGD). <i>Clinical Rheumatology</i> , 2012, 31, 429-434.	2.2	22
82	Characterization of Knee Osteoarthritis in Latin America. A Comparative Analysis of Clinical and Health Care Utilization in Argentina, Brazil, and Mexico. <i>Reumatología Clínica</i> , 2014, 10, 152-159.	0.5	22
83	Extension Study of PF-05280586 , a Potential Rituximab Biosimilar, Versus Rituximab in Subjects With Active Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2018, 70, 1598-1606.	3.4	22
84	The juvenile-onset spondyloarthritis: rationale for clinical evaluation. <i>Best Practice and Research in Clinical Rheumatology</i> , 2002, 16, 551-572.	3.3	21
85	Comparison of two schedules for administering oral low-dose methotrexate (weekly versus) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T randomized study. <i>Arthritis and Rheumatism</i> , 1999, 42, 2160-2165.	6.7	20
86	Innate immunity in host-microbial interactions: Beyond B27 in the spondyloarthropathies. <i>Current Opinion in Rheumatology</i> , 2002, 14, 373-382.	4.3	20
87	Prevalence of Back Pain in the Community. A COPCORD-Based Study in the Mexican Population. <i>Journal of rheumatology Supplement, The</i> , 2011, 86, 26-30.	2.2	18
88	Association of Regional and Cultural Factors With the Prevalence of Rheumatoid Arthritis in the Mexican Population. <i>Journal of Clinical Rheumatology</i> , 2015, 21, 57-62.	0.9	18
89	Bone Lineage Proteins in the Enteses of the Midfoot in Patients with Spondyloarthritis. <i>Journal of Rheumatology</i> , 2015, 42, 630-637.	2.0	17
90	Juvenile Spondyloarthritis Treatment Recommendations. <i>American Journal of the Medical Sciences</i> , 2012, 343, 367-370.	1.1	16

#	ARTICLE	IF	CITATIONS
91	A Community-Based Study on the Prevalence of Spondyloarthritis and Inflammatory Back Pain in Mexicans. <i>Journal of Clinical Rheumatology</i> , 2013, 19, 57-61.	0.9	16
92	Efficacy and Safety of Tocilizumab for Polyarticular Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial. <i>Arthritis and Rheumatology</i> , 2021, 73, 530-541.	5.6	16
93	Epidemiology of Spondyloarthritis in México. <i>American Journal of the Medical Sciences</i> , 2011, 341, 298-300.	1.1	15
94	Ankylosing spondylitis and reactive arthritis in the developing world. <i>Best Practice and Research in Clinical Rheumatology</i> , 2008, 22, 709-723.	3.3	14
95	Are Target Urate and Remission Possible in Severe Gout? A Five-year Cohort Study. <i>Journal of Rheumatology</i> , 2020, 47, 132-139.	2.0	14
96	High response rate in the phase I/III study of meloxicam in juvenile rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2002, 29, 1079-83.	2.0	14
97	Very recent onset arthritis: the value of initial rheumatologist evaluation and anti-cyclic citrullinated peptide antibodies in the diagnosis of rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2009, 28, 1135-1139.	2.2	13
98	Towards Elucidation of the Epidemiology of the Rheumatic Diseases in Mexico. <i>COPCORD Studies in the Community. Journal of rheumatology Supplement, The</i> , 2011, 86, 1-2.	2.2	13
99	The Social Gap Index and the prevalence of osteoarthritis in the community: a cross-sectional multilevel study in Mexico. <i>Clinical Rheumatology</i> , 2016, 35, 175-182.	2.2	13
100	Syndemic and syndemogenesis of low back pain in Latin-American population: a network and cluster analysis. <i>Clinical Rheumatology</i> , 2020, 39, 2715-2726.	2.2	13
101	Undifferentiated spondyloarthritis: A global perspective. <i>Current Rheumatology Reports</i> , 2007, 9, 361-366.	4.7	12
102	From Retrospective Analysis of Patients with Undifferentiated Spondyloarthritis (SpA) to Analysis of Prospective Cohorts and Detection of Axial and Peripheral SpA. <i>Journal of Rheumatology</i> , 2010, 37, 1091-1095.	2.0	12
103	Assessment of clinical efficacy and safety in a randomized double-blind study of etanercept and sulfasalazine in patients with ankylosing spondylitis from Eastern/Central Europe, Latin America, and Asia. <i>Rheumatology International</i> , 2016, 36, 643-651.	3.0	12
104	Epidemiology of rheumatic diseases in indigenous populations in Latin-Americans. <i>Clinical Rheumatology</i> , 2016, 35, 1-3.	2.2	12
105	Response to secukinumab on synovitis using Power Doppler ultrasound in psoriatic arthritis: 12-week results from a phase III study, ULTIMATE. <i>Rheumatology</i> , 2022, 61, 1867-1876.	1.9	11
106	Problemas con el uso de sillas de ruedas y otras ayudas técnicas y barreras sociales a las que se enfrentan las personas que las utilizan. Estudio cualitativo desde la perspectiva de la ergonomía en personas discapacitadas por enfermedades reumáticas y otras condiciones. <i>Reumatología Clínica</i> , 2013, 9, 24-30.	0.5	10
107	Recognition of B cells epitopes of the <i>Klebsiella pneumoniae</i> GroEL-like protein by HLA-B27 positive subjects. <i>Microbial Pathogenesis</i> , 2000, 28, 211-220.	2.9	9
108	The 30-kDa band from <i>Salmonella typhimurium</i> : IgM, IgA and IgG antibody response in patients with ankylosing spondylitis. <i>Rheumatology</i> , 2009, 48, 748-754.	1.9	9

#	ARTICLE	IF	CITATIONS
109	â€Not-Belonging': Illness Narratives of Mexican Patients with Ankylosing Spondylitis. <i>Medical Anthropology: Cross Cultural Studies in Health and Illness</i> , 2013, 32, 487-500.	1.2	9
110	Severe tophaceous gout and disability: changes in the past 15 years. <i>Clinical Rheumatology</i> , 2017, 36, 199-204.	2.2	9
111	A case of childhood-onset ankylosing spondylitis: diagnosis and treatment. <i>Nature Clinical Practice Rheumatology</i> , 2009, 5, 52-57.	3.2	8
112	CD4 and CD8 T cell response to the rHSP60 from <i>Klebsiella pneumoniae</i> in peripheral blood mononuclear cells from patients with ankylosing spondylitis. <i>Revista De Investigacion Clinica</i> , 2005, 57, 555-62.	0.4	8
113	Inflammatory Back Pain. <i>Rheumatic Disease Clinics of North America</i> , 2012, 38, 487-499.	1.9	7
114	Clinical Experiences with the Intramuscular Injection of Tiaprofenic Acid in Rheumatic Diseases, with Particular Emphasis on Time of Onset and Duration of the Analgesic Effect. <i>Drugs</i> , 1988, 35, 72-80.	10.9	6
115	From undifferentiated SpA to ankylosing spondylitis. <i>Nature Reviews Rheumatology</i> , 2013, 9, 639-641.	8.0	6
116	A3: Efficacy and Safety of Adalimumab in Pediatric Patients With Enthesitis Related Arthritis. <i>Arthritis and Rheumatology</i> , 2014, 66, S4.	5.6	6
117	Health related quality of life measure in systemic pediatric rheumatic diseases and its translation to different languages: an international collaboration. <i>Pediatric Rheumatology</i> , 2014, 12, 49.	2.1	6
118	Improvement in OMERACT domains and renal function with regular treatment for gout: a 12-month follow-up cohort study. <i>Clinical Rheumatology</i> , 2018, 37, 1885-1894.	2.2	6
119	The Use of Glucocorticoids by Rheumatologic Patients Before Attending a Specialized Department in MÃ©xico. <i>Journal of Clinical Rheumatology</i> , 2008, 14, 148-152.	0.9	5
120	Usage Problems and Social Barriers Faced by Persons With a Wheelchair and Other Aids. Qualitative Study From the Ergonomics Perspective in Persons Disabled by Rheumatoid Arthritis and Other Conditions. <i>ReumatologÃ­a ClÃ­nica (English Edition)</i> , 2013, 9, 24-30.	0.3	5
121	A14: Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk in Patients With Systemic Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2014, 66, S23-S24.	5.6	5
122	Bone Proliferation in Ankylosing Tarsitis Might Involve Mechanical Stress, and Hormonal and Growth Factors. <i>Journal of Rheumatology</i> , 2015, 42, 2210-2210.	2.0	5
123	Association of ERAP2 polymorphisms in Colombian HLA-B27+ or HLA-B15+ patients with SpA and its relationship with clinical presentation: axial or peripheral predominance. <i>RMD Open</i> , 2020, 6, e001250.	3.8	5
124	Outcomes in Juvenile-Onset Spondyloarthritis. <i>Frontiers in Medicine</i> , 2021, 8, 680916.	2.6	5
125	Identification of clinical phenotypes of peripheral involvement in patients with spondyloarthritis, including psoriatic arthritis: a cluster analysis in the worldwide ASAS-PerSpA study. <i>RMD Open</i> , 2021, 7, e001728.	3.8	5
126	Gout during the SARS-CoV-2 pandemic: increased flares, urate levels and functional improvement. <i>Clinical Rheumatology</i> , 2021, , 1.	2.2	5

#	ARTICLE	IF	CITATIONS
127	A11: Assessment of Radiographic Progression in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2-Year Data From CHERISH. <i>Arthritis and Rheumatology</i> , 2014, 66, S17-S18.	5.6	4
128	A Prospective Follow-Up of Adipocytokines in Cohort Patients With Gout. <i>Medicine (United States)</i> , 2015, 94, e935.	1.0	4
129	Consenso ASAS en nomenclatura en espa�ol para las espondiloartritis. <i>Reumatolog�a Cl�nica</i> , 2020, 16, 333-338.	0.5	4
130	Subclinical synovitis and tenosynovitis by ultrasonography (US) 7 score in patients with rheumatoid arthritis treated with synthetic drugs, in clinical remission by DAS28. <i>Reumatolog�a Cl�nica</i> , 2019, 15, e5-e9.	0.5	3
131	Differential expression of TLR2 and TLR4 in β 2-microglobulin-positive leukocytes of patients with axial spondyloarthritis. <i>Rheumatology</i> , 2020, 59, 879-888.	1.9	3
132	Determinants of discordance between criteria for inactive disease and low disease activity in juvenile idiopathic arthritis. <i>Arthritis Care and Research</i> , 2020, 73, 1722-1729.	3.4	3
133	P187�Secukinumab significantly decreased joint synovitis measured by Power Doppler ultrasonography in biologic-naive patients with active psoriatic arthritis: primary (12week) results from a randomised, placebo-controlled Phase 3 study. <i>Rheumatology</i> , 2021, 60, .	1.9	3
134	Results from a cross-sectional, observational study to assess inadequate pain relief in patients with knee and/or hip osteoarthritis in Mexico. <i>Reumatolog�a Cl�nica (English Edition)</i> , 2021, 17, 397-403.	0.3	3
135	Results from a cross-sectional, observational study to assess inadequate pain relief in patients with knee and/or hip osteoarthritis in Mexico. <i>Reumatolog�a Cl�nica</i> , 2021, 17, 397-403.	0.5	3
136	Inflammatory Foot Involvement in Spondyloarthritis: From Tarsitis to Ankylosing Tarsitis. <i>Frontiers in Medicine</i> , 2021, 8, 730273.	2.6	3
137	Challenges in juvenile-onset spondyloarthritis. <i>International Journal of Clinical Rheumatology</i> , 2010, 5, 229-239.	0.3	2
138	Current therapies in rheumatoid arthritis: A Latin American perspective. <i>Reumatolog�a Cl�nica (English)</i> Tj ETQq0 0.0 rgBT /Qverlock 10	0.3	2
139	Stress proteins in the pathogenesis of spondyloarthritis. <i>Rheumatology International</i> , 2019, 39, 595-604.	3.0	2
140	Juvenile Ankylosing Spondylitis. , 2012, , 1601-1609.		2
141	A Wearable System Based on Multiple Magnetic and Inertial Measurement Units for Spine Mobility Assessment: A Reliability Study for the Evaluation of Ankylosing Spondylitis. <i>Sensors</i> , 2022, 22, 1332.	3.8	2
142	Chapter 2 The Juvenile-Onset Spondyloarthritis. <i>Handbook of Systemic Autoimmune Diseases</i> , 2007, , 15-33.	0.1	1
143	REACTIVE ARTHRITIS. , 2011, , 591-599.		1
144	Reply. <i>Arthritis Care and Research</i> , 2016, 68, 1053-1054.	3.4	1

#	ARTICLE	IF	CITATIONS
145	If three of my brothers have ankylosing spondylitis, why does the doctor say it is not necessarily hereditary? The meaning of risk in multiplex case families with ankylosing spondylitis. <i>Chronic Illness</i> , 2016, 12, 58-70.	1.5	1
146	Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies. <i>Reumatología Clínica</i> , 2019, 15, 43-53.	0.5	1
147	Peripheral neuropathies in rheumatic diseases: More diverse and frequent than expected. A cross-sectional study. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 226-232.	1.9	1
148	Preliminary tests of an Inertial Measurement Units based System for Spine mobility assessment in patients with Ankylosing Spondylitis. , 2021, 2021, 7124-7127.		1
149	A169: Cumulative Long-Term Safety, Efficacy and Patient-Reported Outcomes in Children With Juvenile Idiopathic Arthritis Treated With Intravenous Abatacept: Up to 7 Years of Treatment. <i>Arthritis and Rheumatology</i> , 2014, 66, S218-S219.	5.6	0
150	Characterization of Knee Osteoarthritis in Latin America. A Comparative Analysis of Clinical and Health Care Utilization in Argentina, Brazil, and Mexico. <i>Reumatología Clínica (English Edition)</i> , 2014, 10, 152-159.	0.3	0
151	Computer vision system for evaluating the Schober's test. <i>AIP Conference Proceedings</i> , 2016, , .	0.4	0
152	Reactive Arthritis. , 2016, , 563-570.e3.		0
153	The Mexican Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 283-289.	3.0	0
154	The Paraguayan Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 307-313.	3.0	0
155	Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies. <i>Reumatología Clínica (English Edition)</i> , 2019, 15, 43-53.	0.3	0
156	Recommendations of the Mexican College of Rheumatology for the management of spondyloarthritis. <i>Reumatología Clínica (English Edition)</i> , 2021, 17, 37-45.	0.3	0
157	The juvenile-onset spondyloarthropathies. , 2011, , 1029-1034.e1.		0
158	Juvenile-onset spondyloarthritis. , 2015, , 862-867.		0